Abstracts tagged "Disease Activity"

Abstract Number: 2270 • ACR Convergence 2023
Factors Associated with Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Systemic Lupus Erythematosus: An International Collaborative Study
Shounak Ghosh¹, Rajagopal Sankara Narayanan², Katie Bechman³, Ioannis Parodis⁴, Esha Kadam⁵, Wanruchada Katchamart⁶, Phonpen Akarawatcharangura Goo⁷, Abraham Edgar Gracia-Ramos⁸, Parikshit Sen⁹, Elena Nikiphorou³, Sreoshy Saha¹⁰, Ai Lyn Tan¹¹, Tsvetelina Velikova¹², Marcin Milchert¹³, Johannes Knitza¹⁴, Carlo Caballero¹⁵, Dey Dzifa¹⁶, Hector Chinoy¹⁷, COVAD Study Group¹⁸, Rohit Aggarwal¹⁹, Vikas Agarwal²⁰, Latika Gupta²¹ and Chris Wincup²², ¹CMRI Hospital, Kolkata, India, ²Narayana Medical College, Nellore, India, ³King's College London, London, United Kingdom, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ⁶Mahidol University, Bangkok, Thailand, ⁷Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ⁸Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ⁹Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁰Mymensingh Medical College, Faridpur, Bangladesh, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹³Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁴Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ¹⁵Universidad del Norte, Barranquilla, Colombia, ¹⁶Department of Medicine and Therapeutics, University of Ghana School of Medicine and Dentistry, College of Health Sciences, Korle-Bu, Accra, Ghana, ¹⁷The University of Manchester, Sale, United Kingdom, ¹⁸-, -, ¹⁹University of Pittsburgh, Pittsburgh, PA, ²⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²¹Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ²²King's College Hospital, London, United Kingdom
Background/Purpose: The management of SLE relies on regular assessment of disease activity. However, patient perception of disease activity can be highly variable and may be…
Abstract Number: 2484 • ACR Convergence 2023
Optimizing the Care of the Rheumatic Patient with Rheumatologist-Pharmacist Co-management
Ruchi Patel¹, Kristen Salava¹, Eric Newman², Joseph Chronowski¹, Dante Grassi¹, Hillary Harris³, Amanda Young¹, Idorenyin Udoeyo², Lisa Schroeder², David Bulbin⁴, David Pugliese⁵ and Jonida Cote⁶, ¹Geisinger Medical Center, Danville, PA, ²Geisinger, Danville, PA, ³Geisinger, Wilkes Barre, PA, ⁴Geisinger Health System, Danville, PA, ⁵Geisinger Health System, Wilkes-Barre, PA, ⁶Geisinger Medical Center, Orefield, PA
Background/Purpose: More effective teamwork can improve patient care. We studied the effect of a Rheumatologist-Pharmacist Co-management program on the quality of care of rheumatology patients…
Abstract Number: 0377 • ACR Convergence 2023
Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis
Melissa Mannion¹, Monica Aswani², Kristine Hearld², Emily Smitherman², Livie Huie³ and Jeffrey R Curtis⁴, ¹University of Alabama at Brimingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL
Background/Purpose: The goal of treatment for patients with juvenile idiopathic arthritis (JIA) is inactive or minimal disease activity and escalating medication for active disease is…
Abstract Number: 0533 • ACR Convergence 2023
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?
Francesco Natalucci¹, Pauline KRUG², Angela DE SOUSA LEITE², Tatiana Sokolova³, Patrick Durez⁴, Maria S. Stoenoiu² and Adrien NZEUSSEU TOUKAP⁵, ¹UCLouvain University, Sermoneta, Italy, ²Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Université Catholique de Louvain, Brussels, Belgium, ⁴UCLouvain, Brussels, Belgium, ⁵Cliniques universitaires Saint-Luc, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (axSpA) patients have shown that remission in axSpA (including nonradiographic axSpA) patients treated without b/tsDMARDs (TNFα blockers,…
Abstract Number: 0848 • ACR Convergence 2023
Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients
Kishan Majithiya¹, Komal Singh¹, Pankti Mehta², Chengappa Kavadichanda³, seema Sharma¹, Able Lawrence¹ and Amita Aggarwal¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²King George's Medical University, Mumbai, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Disease flare and infections are the major causes of fever in a patient with SLE. It is vital to differentiate between these two as…
Abstract Number: 1218 • ACR Convergence 2023
Discovering the Potential Application of Digital Biomarkers for Inflammatory Arthritis Patients, a Design Thinking Approach; Preliminary Results of the Patients’ Perspective
patty de Groot¹, ilja Tchetverikov², Yvonne P. M. Goekoop-Ruiterman³, Wendy Olsder⁴, Rien Bakker⁵, Marc r. Kok⁶, Jasper Foolen⁷ and Jolanda J. Luime¹, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Albert Sweitzer Hospital, Dordrecht, Netherlands, ³Haga Ziekenhuis, The Hague, Netherlands, ⁴Erasmus School of Health Policy and Management, Rotterdam, Netherlands, ⁵Consortium Beroepsonderwijs, Information Communication Technology, Amersfoort, Netherlands, ⁶Maasstad Hospital, Rotterdam, Netherlands, ⁷Eindhoven University of Technology deparment of Biomedical Engineering, Eindhoven, Netherlands
Background/Purpose: The Inflammatory Arthritis (IA) patient population is growing, whilst facing a shortage of health care professionals (HCPs). It is impossible to meet the future…
Abstract Number: 1382 • ACR Convergence 2023
Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome
Qinghong Liu¹ and Jing He², ¹Peking University People's Hospital, Beijing, China, ²Peking University People’s Hospital, Beijing, China
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by systemic involvement and lacks effective treatment options. The Janus kinase (JAK) pathway plays a…
Abstract Number: 1452 • ACR Convergence 2023
Inflammatory Markers and Left Ventricular Dysfunction in Systemic Lupus Erythematosus (SLE)
Audrey Hagiwara, Moumita Bose, Marianne Bernardo, Michael Nelson, Mariko Ishimori, Daniel Berman, C. Noel Bairey Merz, janet wei and Caroline Jefferies, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Women with SLE have an elevated risk of cardiovascular disease. Many women with SLE frequently report chest pain in the absence of obstructive coronary…
Abstract Number: 1936 • ACR Convergence 2023
Higher Rates of Disease Control During the Coronavirus Pandemic in Pediatric Patients with Autoinflammatory Periodic Diseases on Canakinumab Treatment – Interim Data from the RELIANCE Registry
Gerd Horneff¹, Norbert Blank², Jasmin B. Kuemmerle-Deschner³, Joerg Henes⁴, Birgit Kortus-Goetze⁵, Prasad T. Oommen⁶, Anne Pankow⁷, Tobias Krickau⁸, Catharina Schuetz⁹, Ivan Foeldvari¹⁰, Juergen Rech¹¹, Frank Weller-Heinemann¹², Ales Janda¹³, Markus Hufnagel¹⁴, Florian M. Meier¹⁵, Frank Dressler¹⁶, Michael Borte¹⁷, Ioana Andreica¹⁸, Peter Wasiliew¹⁹, Michael Fiene²⁰, Daniel Windschall²¹, Martin Krusche²², Tania Kuempfel²³, Julia Weber-Arden²⁴ and Tilmann Kallinich²⁵, ¹Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ²University Hospital Heidelberg, Heidelberg, Germany, ³med.uni-tuebingen, Tübingen, Germany, ⁴University Hospital Tuebingen, Tuebingen, Germany, ⁵Department of Internal Medicine, Division of Nephrology,University Hospital of Giessen and Marburg, Marburg, Germany, ⁶Department of Pediatric Oncology, Hematology and Clinical Immunology, Center for Child and Adolescent Health,Medical Faculty Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁷Department of Rheumatology and Clinical Immunology,Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Pediatrics, Friedrich-Alexander University Erlangen-Nuernberg (FAU), Erlangen, Germany, ⁹Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus,Technische Universität Dresden, Dresden, Germany, ¹⁰Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹¹University Clinic Erlangen, Erlangen, Germany, ¹²Division of Pediatric Rheumatology, Prof. Hess Children's Hospital, Bremen, Bremen, Germany, ¹³Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany, ¹⁴Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹⁵Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, Frankfurt am Main, Germany, ¹⁶Department of Paediatric Pneumology, Allergology and Neonatology, Children's Hospital, Hannover Medical School, Hannover, Germany, ¹⁷Hospital for Children & Adolescents, St. Georg Hospital, Leipzig, Germany, ¹⁸Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ¹⁹Division of Pediatric Rheumatology and autoinflammation reference center Tuebingen, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ²⁰Rheumatology Center Greifswald, Greifswald, Germany, ²¹Clinic of Paediatric and Adolescent Rheumatology, St. Josef-Stift Sendenhorst, Northwest German Center for Rheumatology, Sendenhorst, Germany, ²²UKE, Hamburg, Germany, ²³Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universität München, Muenchen, Germany, ²⁴Novartis Innovative Medicines, Nuernberg, Germany, ²⁵Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Nuremberg, Germany
Background/Purpose: Pediatric patients with autoinflammatory diseases (AID) on Canakinumab (CAN) therapy have been affected by the coronavirus pandemic including SARS-CoV-2 infection, SARS-CoV-2 vaccination, and AID…
Abstract Number: 2271 • ACR Convergence 2023
Longitudinal Changes in Type 1 & Type 2 SLE Activity
Amanda Eudy¹, Jennifer Rogers², Daniel Wojdyla³, Kai Sun², Rebecca Sadun², Mithu Maheswaranathan⁴, Jayanth Doss², Lisa Criscione-Schreiber⁴ and Megan Clowse⁵, ¹Duke University, Raleigh, NC, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Chapel Hill, NC
Background/Purpose: The Type 1 & 2 SLE Model encompass symptoms classically attributed to inflammation, including arthritis, rash, serositis and nephritis (Type 1 SLE), and symptoms…
Abstract Number: 2513 • ACR Convergence 2023
Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Laura Cappelli¹, Jamie Perin², Clifton Bingham³ and Ami Shah⁴, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: : Immune checkpoint inhibitors (ICI) for cancer treatment can cause inflammatory arthritis (IA). ICI-IA is a heterogeneous entity affecting peripheral joints, tendons, and rarely…
Abstract Number: 0386 • ACR Convergence 2023
Functional Disability and Disease Activity Are Affected by Social Determinants of Health in Patients with Rheumatoid Arthritis
Mohammad Movahedi¹, Kangping Cui², George Tomilnson³, Angela Cesta³, xiuying Li³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Sunnybrook Hospital, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: The relationship between social determinants of health (SDH) (e.g. income, education, and employment status) and disease outcomes in the RA population is not well…
Abstract Number: 0539 • ACR Convergence 2023
Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis
Maxime Dougados¹, David Bulbin², Heather Jones³, Tianming Gao⁴, Anna Shmagel⁵, Thomas Poznanski⁶, Abhijeet Danve⁷ and Karl Gaffney⁸, ¹Université de Paris, Paris, France, ²Geisinger Health System, Danville, PA, ³AbbVie, Inc., Mettawa, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Long Grove, IL, ⁶AbbVie, Inc., Plainfield, IL, ⁷Yale University, New Haven, CT, ⁸Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom
Background/Purpose: Axial SpA (axSpA) and FM manifest with overlapping clinical features such as pain, fatigue, and stiffness, yet their treatment is distinctly different. FM is…
Abstract Number: 0911 • ACR Convergence 2023
Spatial Transcriptomics Reveals Normal-density and Low-density Neutrophils Are More Prevalent Than Macrophages in Lupus Nephritis Glomeruli, and Urine DNA Methylation Analyses Capture Both Myeloid Populations
Sladjana Skopelja-Gardner¹, Joshua Skydel², Alecia Roy³, Brenna Kerin³, James Whitley³, Fred Kolling⁴, Noelle Kosarek⁴, Michelle Petri⁵, Andrea Fava⁶, Lucas Salas⁷ and Christopher Burns³, ¹Department of Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Dartmouth-Hitchcock Medical Center, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁶Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Despite compelling evidence that normal-density (NDN) and low-density neutrophils (LDN) are activated in the blood of lupus patients, their role in lupus nephritis (LN)…
Abstract Number: 1236 • ACR Convergence 2023
Melanoma Differentiation-Associated Protein-5 in Juvenile Dermatomyositis: A Single Center Cohort
Dawn Gist¹, Sarah Molina², Maria Pereira³, Andrea Ramirez³, Cagri Yildirim-Toruner⁴ and Marietta De Guzman³, ¹Baylor College of Medicine Pediatrics Residency, Houston, TX, ²Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy that causes muscle weakness, rash, vascular changes, or other organ involvement. The phenotypes may vary, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].